Invention Grant
- Patent Title: PD-L1 targeting DNA vaccine for cancer immunotherapy
-
Application No.: US16494629Application Date: 2018-03-16
-
Publication No.: US11357842B2Publication Date: 2022-06-14
- Inventor: Heinz Lubenau
- Applicant: VAXIMM AG
- Applicant Address: CH Basel
- Assignee: VAXIMM AG
- Current Assignee: VAXIMM AG
- Current Assignee Address: CH Basel
- Agency: McNeill Baur PLLC
- Priority: EP17161666 20170317,EP17188941 20170901
- International Application: PCT/EP2018/056721 WO 20180316
- International Announcement: WO2018/167290 WO 20180920
- Main IPC: A61K39/112
- IPC: A61K39/112 ; A61K39/00 ; C12N15/74
Abstract:
The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.
Public/Granted literature
- US20200085928A1 NOVEL PD-L1 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY Public/Granted day:2020-03-19
Information query
